These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16772610)

  • 1. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
    Bradeen HA; Eide CA; O'Hare T; Johnson KJ; Willis SG; Lee FY; Druker BJ; Deininger MW
    Blood; 2006 Oct; 108(7):2332-8. PubMed ID: 16772610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
    von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
    Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
    Eide CA; Adrian LT; Tyner JW; Mac Partlin M; Anderson DJ; Wise SC; Smith BD; Petillo PA; Flynn DL; Deininger MW; O'Hare T; Druker BJ
    Cancer Res; 2011 May; 71(9):3189-95. PubMed ID: 21505103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
    O'Hare T; Walters DK; Stoffregen EP; Jia T; Manley PW; Mestan J; Cowan-Jacob SW; Lee FY; Heinrich MC; Deininger MW; Druker BJ
    Cancer Res; 2005 Jun; 65(11):4500-5. PubMed ID: 15930265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
    Koldehoff M; Kordelas L; Beelen DW; Elmaagacli AH
    Haematologica; 2010 Mar; 95(3):388-97. PubMed ID: 20207846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
    Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
    Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
    Tauchi T; Okabe S; Ashihara E; Kimura S; Maekawa T; Ohyashiki K
    Oncogene; 2011 Jun; 30(24):2789-97. PubMed ID: 21278787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
    Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
    Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
    Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
    Hochhaus A; La Rosée P; Müller MC; Ernst T; Cross NC
    Cell Cycle; 2011 Jan; 10(2):250-60. PubMed ID: 21220945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
    Xing H; Liu T; Meng W; Gong Y
    Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of response to imatinib: mechanisms and management.
    Shah NP
    Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
    Goulden S; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
    [No Abstract]   [Full Text] [Related]  

  • 20. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.